Has Johnny Nacilla, MD received payments from drug or device companies?

Yes. Drug and device makers reported $23,206 in general payments to Johnny Nacilla, MD across 1,151 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Johnny Nacilla, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Johnny Nacilla, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Johnny Nacilla, MD

Medical Oncology · Cullman, ALNPI 1346261526

Payments from drug & device makers

$23,206in general payments, 2019–2025

Across 1,151 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$4K
AstraZeneca$2K
Pfizer$1K
Johnson & Johnson$1K
Amgen$1K
E.r. Squibb & Sons, L.L.C.$969
plus $12K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	141	$3,853
AstraZeneca(2 entities)	100	$2,003
Pfizer	66	$1,179
Johnson & Johnson(3 entities)	59	$1,173
Amgen	64	$1,171
E.r. Squibb & Sons, L.L.C.	72	$969
Incyte Corporation	39	$884
Bristol Myers Squibb	42	$797
Daiichi Sankyo Inc.	45	$774
Lilly USA, LLC	54	$702
Regeneron Healthcare Solutions, Inc.	28	$583
Seagen Inc.	29	$573
Sanofi	24	$539
Genentech USA, Inc.	28	$533
GSK	30	$501
AbbVie	22	$495
Sobi, Inc	15	$460
Pharmacyclics LLC, An Abbvie Company	20	$427
Merck	18	$350
Boehringer Ingelheim	16	$332
Dova Pharmaceuticals	12	$266
Pharmaessentia USA Corporation	9	$263
Bayer	13	$213
Dendreon Pharmaceuticals LLC	7	$209
Jazz Pharmaceuticals Inc.	5	$207
Karyopharm Therapeutics Inc.	11	$206
Array Biopharma Inc	11	$198
Gilead(2 entities)	11	$189
Eisai Inc.	10	$178
Stemline Therapeutics Inc.	7	$170
Sumitomo Pharma America, Inc.	9	$161
AVEO Pharmaceuticals, Inc.	4	$149
Beigene USA, Inc.	8	$148
Tersera Therapeutics LLC	7	$140
Blueprint Medicines Corporation	6	$138
Astellas Pharma US Inc	7	$138
EMD Serono, Inc.	6	$121
Kyowa Kirin, Inc.	6	$115
Myriad Genetic Laboratories, Inc.	6	$111
Puma Biotechnology, Inc.	6	$110
Coherus Oncology, Inc.	6	$105
Taiho Oncology, Inc.	6	$100
Rigel Pharmaceuticals, Inc.	5	$87
Takeda Pharmaceuticals U.S.A., Inc.	3	$79
Exelixis Inc.	4	$77
ADC Therapeutics America, Inc.	3	$76
Acrotech Biopharma Inc.	4	$71
Spectrum Pharmaceuticals Inc.	3	$63
Beone Medicines USA, Inc.	3	$56
Pharmacosmos Therapeutics Inc.	3	$49
Genmab U.S., Inc.	2	$43
Geron Corporation	2	$42
Tesaro, Inc.	2	$41
Partner Therapeutics, Inc.	2	$40
Celltrion USA Inc.	1	$36
Medtronic(2 entities)	2	$35
Myovant Sciences Inc.	2	$35
AMAG Pharmaceuticals, Inc.	2	$28
Mirati Therapeutics, Inc.	1	$27
Verastem, Inc.	2	$27

How this compares

$23,206 in reported general payments places this provider in the 65th percentile of 30 medical oncology providers in Alabama.

See all medical oncology providers in Alabama →

Medicare billing

Part B allowed, 2024

$2,177,599

Medicare patients

511

Services billed

115,281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Cullman

Syed Abbas AliJasper$3M
Joelle HamiltonHomewood$2.2M
Sachin PaiMobile$2.1M
Marshall SchreederHuntsville$1.1M
Pranitha ProdduturvarMobile$910K
John DubayTuscaloosa$756K
Sunil RangarajanBirmingham$576K
James DaughertyFlorence$119K
Hemant PatelMuscle Shoals$61K
Michael GarciaJasper$23K

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →